• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞培养来源的丙型肝炎病毒诱导的中和抗体可预防小鼠感染。

Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.

机构信息

Pharmaceutical Research Laboratories, Toray Industries, Inc, Kanagawa, Japan.

出版信息

Gastroenterology. 2013 Aug;145(2):447-55.e1-4. doi: 10.1053/j.gastro.2013.05.007. Epub 2013 May 11.

DOI:10.1053/j.gastro.2013.05.007
PMID:23673355
Abstract

BACKGROUND & AIMS: Hepatitis C virus (HCV) infection is a major cause of liver cancer, so strategies to prevent infection are needed. A system for cell culture of infectious HCV particles (HCVcc) has recently been established; the inactivated HCVcc particles might be used as antigens in vaccine development. We aimed to confirm the potential of HCVcc as an HCV particle vaccine.

METHODS

HCVcc derived from the J6/JFH-1 chimeric genome was purified from cultured cells by ultrafiltration and ultracentrifugation purification steps. Purified HCV particles were inactivated and injected into female BALB/c mice with adjuvant. Sera from immunized mice were collected and their ability to neutralize HCV was examined in naive Huh7.5.1 cells and urokinase-type plasminogen activator-severe combined immunodeficiency mice (uPA(+/+)-SCID mice) given transplants of human hepatocytes (humanized livers).

RESULTS

Antibodies against HCV envelope proteins were detected in the sera of immunized mice; these sera inhibited infection of cultured cells with HCV genotypes 1a, 1b, and 2a. Immunoglobulin G purified from the sera of HCV-particle-immunized mice (iHCV-IgG) inhibited HCV infection of cultured cells. Injection of IgG from the immunized mice into uPA(+/+)-SCID mice with humanized livers prevented infection with the minimum infectious dose of HCV.

CONCLUSIONS

Inactivated HCV particles derived from cultured cells protect chimeric liver uPA(+/+)-SCID mice against HCV infection, and might be used in the development of a prophylactic vaccine.

摘要

背景与目的

丙型肝炎病毒(HCV)感染是肝癌的主要病因,因此需要采取预防感染的策略。最近已经建立了一种用于培养感染性 HCV 颗粒(HCVcc)的细胞培养系统;失活的 HCVcc 颗粒可能被用作疫苗开发中的抗原。我们旨在确认 HCVcc 作为 HCV 颗粒疫苗的潜力。

方法

通过超滤和超速离心纯化步骤从培养的细胞中纯化来自 J6/JFH-1 嵌合基因组的 HCVcc。纯化的 HCV 颗粒经失活后与佐剂一起注入雌性 BALB/c 小鼠。采集免疫小鼠的血清,并在未感染的 Huh7.5.1 细胞和接受人肝细胞移植的尿激酶型纤溶酶原激活物-严重联合免疫缺陷小鼠(uPA(+/+)-SCID 小鼠)中检测其中和 HCV 的能力。

结果

在免疫小鼠的血清中检测到针对 HCV 包膜蛋白的抗体;这些血清抑制了 HCV 基因型 1a、1b 和 2a 培养细胞的感染。从 HCV 颗粒免疫小鼠的血清中纯化的免疫球蛋白 G(iHCV-IgG)抑制了培养细胞中的 HCV 感染。将免疫小鼠的 IgG 注射到具有人源化肝脏的 uPA(+/+)-SCID 小鼠中,可防止感染最小感染剂量的 HCV。

结论

来自培养细胞的失活 HCV 颗粒可保护嵌合肝脏 uPA(+/+)-SCID 小鼠免受 HCV 感染,可能被用于开发预防性疫苗。

相似文献

1
Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice.细胞培养来源的丙型肝炎病毒诱导的中和抗体可预防小鼠感染。
Gastroenterology. 2013 Aug;145(2):447-55.e1-4. doi: 10.1053/j.gastro.2013.05.007. Epub 2013 May 11.
2
Chimeric hepatitis B virus/hepatitis C virus envelope proteins elicit broadly neutralizing antibodies and constitute a potential bivalent prophylactic vaccine.嵌合乙型肝炎病毒/丙型肝炎病毒包膜蛋白可诱导广泛中和抗体,并构成潜在的双价预防性疫苗。
Hepatology. 2013 Apr;57(4):1303-13. doi: 10.1002/hep.26132. Epub 2013 Mar 14.
3
Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.口服免疫减毒沙门氏菌携带 co-expression 质粒,编码丙型肝炎病毒的核心和 E2 蛋白,能够在小鼠中诱导细胞免疫应答和中和抗体。
Vaccine. 2011 May 9;29(20):3714-23. doi: 10.1016/j.vaccine.2011.02.083. Epub 2011 Mar 9.
4
Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.用嵌合乙型肝炎病毒样颗粒进行免疫接种以诱导潜在的抗丙型肝炎病毒中和抗体。
Antivir Ther. 2007;12(4):477-87.
5
Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine.E2 高变区 (HVR1) 在重组丙型肝炎病毒疫苗免疫原性中的作用。
J Virol. 2018 May 14;92(11). doi: 10.1128/JVI.02141-17. Print 2018 Jun 1.
6
[Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice].[丙型肝炎病毒包膜蛋白2 DNA疫苗诱导小鼠产生中和抗体的研究]
Wei Sheng Yan Jiu. 2011 May;40(3):295-8.
7
N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses.N-糖基化突变的丙型肝炎病毒包膜糖蛋白复合物增强抗原呈递活性以及细胞和中和抗体反应。
Biochim Biophys Acta. 2016 Aug;1860(8):1764-75. doi: 10.1016/j.bbagen.2015.08.007. Epub 2015 Aug 14.
8
Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes.嵌合乙型肝炎病毒表面抗原病毒样颗粒诱导的抗体对丙型肝炎病毒中和表位的中和作用。
Vaccine. 2018 Apr 19;36(17):2273-2281. doi: 10.1016/j.vaccine.2018.03.036. Epub 2018 Mar 22.
9
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.一种重组丙型肝炎病毒 1a 型 E1/E2 包膜糖蛋白疫苗可诱导产生抗体,通过 E2 的 N 端高变区 1 与清道夫受体 B1 的相互作用,使这些抗体对密切相关的 2a 株产生不同的中和作用。
J Virol. 2019 Oct 29;93(22). doi: 10.1128/JVI.00810-19. Print 2019 Nov 15.
10
Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.靶向丙型肝炎病毒糖蛋白新型中和表位的抗体可预防2型病毒感染。
PLoS One. 2015 Sep 25;10(9):e0138756. doi: 10.1371/journal.pone.0138756. eCollection 2015.

引用本文的文献

1
Targets of protective immunity and opportunities in hepatitis C virus vaccine development.丙型肝炎病毒疫苗开发中的保护性免疫靶点与机遇
Nat Rev Immunol. 2025 Sep 12. doi: 10.1038/s41577-025-01215-9.
2
Update on Hepatitis C Vaccine: Results and Challenges.丙型肝炎疫苗更新:结果与挑战。
Viruses. 2024 Aug 21;16(8):1337. doi: 10.3390/v16081337.
3
Prospects for developing an Hepatitis C virus E1E2-based nanoparticle vaccine.开发基于丙型肝炎病毒 E1E2 的纳米颗粒疫苗的前景。
Rev Med Virol. 2023 Sep;33(5):e2474. doi: 10.1002/rmv.2474. Epub 2023 Aug 11.
4
Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies.基于诱导中和抗体的当前丙型肝炎疫苗候选物。
Viruses. 2023 May 11;15(5):1151. doi: 10.3390/v15051151.
5
Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.患者来源的单克隆抗体在体外和体内中和 HCV 感染,而不产生逃逸突变体。
PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.
6
Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.基因 1a、2a 和 3a 型灭活 HCV 疫苗候选物在小鼠中诱导了广泛中和抗体。
Gut. 2023 Mar;72(3):560-572. doi: 10.1136/gutjnl-2021-326323. Epub 2022 Aug 2.
7
High-Titer Hepatitis C Virus Production in a Scalable Single-Use High Cell Density Bioreactor.在可扩展的一次性高细胞密度生物反应器中高效生产丙型肝炎病毒
Vaccines (Basel). 2022 Feb 7;10(2):249. doi: 10.3390/vaccines10020249.
8
[Development approaches for vaccines against hepatitis C virus infections].[丙型肝炎病毒感染疫苗的研发方法]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022 Feb;65(2):183-191. doi: 10.1007/s00103-021-03477-9. Epub 2022 Jan 11.
9
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?在基于信使核糖核酸的快速疫苗时代:为什么尚无有效的丙型肝炎病毒疫苗?
World J Hepatol. 2021 Oct 27;13(10):1234-1268. doi: 10.4254/wjh.v13.i10.1234.
10
Antigenic and immunogenic evaluation of permutations of soluble hepatitis C virus envelope protein E2 and E1 antigens.可溶性丙型肝炎病毒包膜蛋白 E2 和 E1 抗原的排列的抗原性和免疫原性评估。
PLoS One. 2021 Jul 30;16(7):e0255336. doi: 10.1371/journal.pone.0255336. eCollection 2021.